Sartorius Stedim Biotech (Paris:DIM), a leading supplier for the
biopharmaceutical industry, today pre-announced results for the first
quarter 2015. Based on preliminary figures sales revenue grew around 22%
in constant currencies to approximately €204 million (reported gain:
Due to the low prior-year revenue base, the company had expected
above-average growth rates for this first quarter. Nevertheless, the
gains supported by strong performance in all product segments were
higher than projected at the beginning of the year.
Based on the results of the first three months, Sartorius Stedim Biotech
has revised its forecast upwards for the full year of 2015. Sales
revenue in constant currencies is now expected to increase approximately
7% to 10% (previous guidance: approx. 4% to 7%). Management projects
that the company‘s underlying EBITDA margin in constant currencies will
reach around 24.5% to 25% (previous guidance: around 24.0% to 24.5%).
Further information will be published on April 20, 2015.
This press release contains statements about the future development of
the Sartorius Stedim Biotech Group. We cannot guarantee that the content
of these statements will actually apply because these statements are
based upon assumptions and estimates that harbor certain risks and
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge products
and services for the development, quality assurance and production
processes of the biopharmaceutical industry. Its integrated solutions
covering fermentation, cell cultivation, filtration, purification, fluid
management and lab technologies are supporting the biopharmaceutical
industry around the world to develop and produce drugs safely, timely
and economically. Sartorius Stedim Biotech focuses on single-use
technologies and value-added services to meet the rapidly changing
technology requirements of the industry it serves. Strongly rooted in
the scientific community and closely allied with customers and
technology partners, the company is dedicated to its philosophy of
“turning science into solutions.”
Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on
the Eurolist of Euronext Paris. With its own manufacturing and R&D sites
in Europe, North America and Asia and a global network of sales
companies, Sartorius Stedim Biotech has a worldwide presence. Its key
manufacturing and R&D site is in Germany. The company employs approx.
3,700 people, and in 2014 earned sales revenue of 683.5 million euros.